NewGenIvf Group (NASDAQ: NIVFW) is a specialized healthcare company focused on assisted reproductive technologies and regenerative health solutions. Founded in 2012 and headquartered in New Delhi, the company operates an expanding network of fertility centers across India. NewGenIvf Group went public in late 2021 through a business combination with a special purpose acquisition company, positioning itself as one of the first ART-focused platforms listed on a U.S. exchange.
The company’s core services encompass in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI) and fertility preservation techniques such as egg and sperm freezing. In addition to these treatments, NewGenIvf Group offers donor programs, preimplantation genetic testing (PGT) and comprehensive reproductive endocrinology consultations. Its clinics are equipped with advanced embryology labs, next-generation sequencing platforms and standardized protocols designed to optimize success rates and patient safety.
NewGenIvf Group has established a presence in major metropolitan areas, including New Delhi, Mumbai, Bangalore, Hyderabad and Kolkata. By combining a telehealth platform for remote consultations with onsite diagnostic and laboratory services, the company seeks to streamline patient access and deliver a coordinated care experience. Its centralized supply chain and digital health infrastructure support consistent quality control across multiple locations.
Under the leadership of Dr. Arindam Ray, who serves as Chief Executive Officer and Medical Director, NewGenIvf Group has grown its clinical team of reproductive specialists, embryologists and geneticists. The company continues to pursue partnerships and strategic investments to broaden its service offerings and explore adjacent opportunities in regenerative medicine and women's health diagnostics.
AI Generated. May Contain Errors.